Therefore, the downregulation of ESR1 and PTGS2 and upregulation of ESR2 by AESN might not only provide antitumor effects against ER+ breast cancer but also afford protective effects towards the development and progression of Parkinson’s disease and Alzheimer’s disease. This evidence concerns the gene ESR2 and breast carcinoma.